Genome Editing Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Genome Editing stocks.

Genome Editing Stocks Recent News

Date Stock Title
May 5 CRSP Wall Street Breakfast: The Week Ahead
May 5 EDIT Wall Street Breakfast: The Week Ahead
May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
May 3 CRSP CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
May 3 CRSP Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 3 ABEO Abeona Therapeutics prices its $75M offering; shares rise
May 3 ABEO Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 2 ABEO Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
May 2 MGX J.P. Morgan downgrades Metagenomi over Moderna deal termination
May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2 CRSP 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 EDIT Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 1 MGX Metagenomi, Moderna terminate gene editing collaboration
May 1 MGX Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
May 1 EDIT Editas, Bristol Myers extend T cell therapy collaboration
May 1 CRSP Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
May 1 EDIT Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 1 DTIL Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Apr 30 CRSP Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
Genome Editing

Genome editing, or genome engineering, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
As of 2015 four families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system. Nine genome editors were available as of 2017.Genome editing with engineered nucleases, i.e. all three major classes of these enzymes—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered meganucleases—were selected by Nature Methods as the 2011 Method of the Year. The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year.

Browse All Tags